U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C73H112N22O16
Molecular Weight 1553.8082
Optical Activity UNSPECIFIED
Defined Stereocenters 16 / 16
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of MUREPAVADIN

SMILES

[H][C@@]12CCCN1C(=O)[C@@]3([H])CCCN3C(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC4=CNC5=CC=CC=C45)NC(=O)[C@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCCN)NC(=O)[C@H](CCN)NC(=O)[C@@]([H])(NC(=O)[C@H](CC6=CNC7=CC=CC=C67)NC(=O)[C@@]([H])(NC2=O)[C@@H](C)O)[C@@H](C)CC

InChI

InChIKey=RIDRXGOBXZLKHZ-NZUANIILSA-N
InChI=1S/C73H112N22O16/c1-5-38(2)58-70(108)88-52(24-30-79)65(103)83-47(17-10-25-74)62(100)85-49(21-27-76)63(101)86-51(23-29-78)66(104)89-53(33-41-35-80-45-15-8-6-13-43(41)45)67(105)87-50(22-28-77)64(102)84-48(20-26-75)61(99)82-39(3)60(98)91-55(37-96)72(110)95-32-12-19-57(95)73(111)94-31-11-18-56(94)69(107)93-59(40(4)97)71(109)90-54(68(106)92-58)34-42-36-81-46-16-9-7-14-44(42)46/h6-9,13-16,35-36,38-40,47-59,80-81,96-97H,5,10-12,17-34,37,74-79H2,1-4H3,(H,82,99)(H,83,103)(H,84,102)(H,85,100)(H,86,101)(H,87,105)(H,88,108)(H,89,104)(H,90,109)(H,91,98)(H,92,106)(H,93,107)/t38-,39-,40+,47-,48-,49+,50-,51-,52-,53-,54-,55-,56-,57+,58-,59-/m0/s1

HIDE SMILES / InChI

Molecular Formula C73H112N22O16
Molecular Weight 1553.8082
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 16 / 16
E/Z Centers 0
Optical Activity UNSPECIFIED

Murepavadin is the first in class of the outer membrane protein-targeting antibiotics (OMPTA) and a pathogen-specific peptidomimetic antibacterial with a novel, nonlytic mechanism of action targeting Pseudomonas aeruginosa. Murepavadin is being developed by Polyphor Ltd for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia. In preclinical studies, Murepavadin was highly effective against Pseudomonas aeruginosa, without evidence of generating resistance. Murepavadin has been evaluated in 8 clinical studies. Murepavadin penetrates into lung tissue and showed encouraging results in a Phase II study when given on top of standard of care in patients with Ventilator-Associated Bacterial Pneumonia. The phase III clinical trial was initiated in 2018 to assess the efficacy, safety, and tolerability of Murepavadin in adult subjects with ventilator-associated bacterial pneumonia. But in May 2019, Polyphor Ltd. suspended the global phase III trial for safety data review.

Approval Year

PubMed

PubMed

TitleDatePubMed
Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa.
2018 Sep 1
Patents

Patents

Sample Use Guides

single dose: Murepavadin 4.5 mg/kg as 3-h IV infusion multiply doses: Murepavadin IV every 8 hours + 1 anti-pseudomonal antibiotic
Route of Administration: Intravenous
Substance Class Chemical
Created
by admin
on Thu Jul 06 10:51:19 UTC 2023
Edited
by admin
on Thu Jul 06 10:51:19 UTC 2023
Record UNII
0D02GRY87Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
MUREPAVADIN
INN   USAN   WHO-DD  
USAN   INN  
Official Name English
POL7080
Code English
murepavadin [INN]
Common Name English
RO-7033877
Code English
Murepavadin [WHO-DD]
Common Name English
RO7033877
Code English
CYCLO(L-ALANYL-L-SERYL-D-PROLYL-L-PROLYL-L-THREONYL-L-TRYPTOPHYL-L-ISOLEUCYL-(2S)-2,4-DIAMINOBUTANOYL-L-ORNITHYL-(2R)-2,4-DIAMINOBUTANOYL-(2S)-2,4-DIAMINOBUTANOYL-L-TRYPTOPHYL-(2S)-2,4-DIAMINOBUTANOYL-(2S)-2,4-DIAMINOBUTANOYL)
Common Name English
POL-7080
Code English
MUREPAVADIN [USAN]
Common Name English
Code System Code Type Description
SMS_ID
100000175060
Created by admin on Thu Jul 06 10:51:19 UTC 2023 , Edited by admin on Thu Jul 06 10:51:19 UTC 2023
PRIMARY
FDA UNII
0D02GRY87Z
Created by admin on Thu Jul 06 10:51:19 UTC 2023 , Edited by admin on Thu Jul 06 10:51:19 UTC 2023
PRIMARY
USAN
DE-85
Created by admin on Thu Jul 06 10:51:19 UTC 2023 , Edited by admin on Thu Jul 06 10:51:19 UTC 2023
PRIMARY
DRUG BANK
DB14777
Created by admin on Thu Jul 06 10:51:19 UTC 2023 , Edited by admin on Thu Jul 06 10:51:19 UTC 2023
PRIMARY
INN
10070
Created by admin on Thu Jul 06 10:51:19 UTC 2023 , Edited by admin on Thu Jul 06 10:51:19 UTC 2023
PRIMARY
PUBCHEM
91824766
Created by admin on Thu Jul 06 10:51:19 UTC 2023 , Edited by admin on Thu Jul 06 10:51:19 UTC 2023
PRIMARY
WIKIPEDIA
Murepavadin
Created by admin on Thu Jul 06 10:51:19 UTC 2023 , Edited by admin on Thu Jul 06 10:51:19 UTC 2023
PRIMARY
NCI_THESAURUS
C175150
Created by admin on Thu Jul 06 10:51:19 UTC 2023 , Edited by admin on Thu Jul 06 10:51:19 UTC 2023
PRIMARY
CAS
944252-63-5
Created by admin on Thu Jul 06 10:51:19 UTC 2023 , Edited by admin on Thu Jul 06 10:51:19 UTC 2023
PRIMARY
Related Record Type Details
TARGET ORGANISM->INHIBITOR
Related Record Type Details
ACTIVE MOIETY